KB-1276

AMG305-MSLN-hIgG1

×
Please enable JavaScript in your browser to complete this form.
12273
Home » Antibodies » AMG305-MSLN-hIgG1

Background of AMG305-MSLN-hIgG1

Mesothelin (MSLN) is a differentiative antigen that is highly expressed in several human tumors, including mesothelioma, ovarian, and pancreatic cancers. As MSLN is overexpressed only in tumor tissues and not in adjacent normal tissues in pancreatic cancer, and is closely associated with tumor progression and migration, it has been proven to be a promising cancer biomarker and an effective target for cancer-targeted therapy.Modification with an anti-MSLN antibody would improve the targeting efficiency of diagnostic imaging agents and the drug-delivery system towards the MSLN-overexpressing pancreatic tumors.

Specifications

Catalog NumberKB-1276
Antibody NameAMG305-MSLN-hIgG1
IsotypeHuman IgG1,kappa
FC MuationsWild Type
TargetMSLN
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA | FACS
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overex-pressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3862.
  2. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
  3. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008;61:235-243.
  4. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12 Pt 1):3937-3942.7
Please enable JavaScript in your browser to complete this form.